Vosoritide an effective treatment to increase growth in children with achondroplasia

An Australian-led phase 3 trial has confirmed that a novel drug vosoritide may be the first effective medication for improving bone growth in children with achondroplasia, the most common form of dwarfism. Children who took the C-type natriuretic peptide analogue for 12 months showed an average annualised growth velocity increase of 1.57cm compared to those who ...

Already a member?

Login to keep reading.

© 2021 the limbic